Neuroblastoma

1. Brisse HJ, McCarville MB, Granata C, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology. 2011 Oct;261(1):243-57.[Abstract][Full Text]

2. Tsubota S, Kadomatsu K. Origin and initiation mechanisms of neuroblastoma. Cell Tissue Res. 2018 May;372(2):211-21.[Abstract]

3. Sainero-Alcolado L, Sjöberg Bexelius T, Santopolo G, et al. Defining neuroblastoma: from origin to precision medicine. Neuro Oncol. 2024 Dec 5;26(12):2174-92.[Abstract][Full Text]

4. Shimada H, Ambros IM, Dehner LP, et al. The international neuroblastoma pathology classification (the Shimada system). Cancer. 1999 Jul 15;86(2):364-72.[Abstract]

5. Pollard ZF, Greenberg MF, Bordenca M, et al. Atypical acquired pediatric Horner syndrome. Arch Ophthalmol. 2010 Jul;128(7):937-40.[Abstract][Full Text]

6. Ogita S, Tokiwa K, Takahashi T, et al. Congenital cervical neuroblastoma associated with Horner syndrome. J Pediatr Surg. 1988 Nov;23(11):991-2.[Abstract]

7. Guo L, Zhang M, Qin L, et al. Superior vena cava occlusion in a 6-year-old child with neuroblastoma: report of a rare case. Asian J Surg. 2024 Nov;47(11):4775-6.[Full Text]

8. Ingram L, Rivera GK, Shapiro DN. Superior vena cava syndrome associated with childhood malignancy: analysis of 24 cases. Med Pediatr Oncol. 1990;18(6):476-81.[Abstract]

9. Zhou J, Jin M, Su Y, et al. Clinical presentation, management, and diagnostic performance of 2021 criteria for paraneoplastic neurologic syndromes in childhood. Neurol Neuroimmunol Neuroinflamm. 2024 May;11(3):e200242.[Abstract][Full Text]

10. Brunklaus A, Pohl K, Zuberi SM, et al. Investigating neuroblastoma in childhood opsoclonus-myoclonus syndrome. Arch Dis Child. 2012 May;97(5):461-3.[Abstract][Full Text]

11. Dornelles Penteado Pacheco E Silva L, Monteiro Caran EM. Vasoactive intestinal peptide-producing neuroblastic tumors: a rare cause of refractory diarrhea. Cureus. 2024 Aug;16(8):e67861.[Abstract][Full Text]

12. Nong J, Su C, Li C, et al. Global, regional, and national epidemiology of childhood neuroblastoma (1990-2021): a statistical analysis of incidence, mortality, and DALYs. EClinicalMedicine. 2024 Dec 6;79:102964.[Abstract][Full Text]

13. Ward E, DeSantis C, Robbins A, et al. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014 Mar-Apr;64(2):83-103.[Abstract][Full Text]

14. Stiller CA, Parkin DM. International variations in the incidence of neuroblastoma. Int J Cancer. 1992 Oct 21;52(4):538-43.[Abstract]

15. National Cancer Institute; National Childhood Cancer Registry Explorer. Neuroblastoma/ganglioneuroblastoma 5-year age-adjusted incidence rates, 2017-2021. Sep 2024 [internet publication].[Full Text]

16. Campbell K, Siegel DA, Umaretiya PJ, et al. A comprehensive analysis of neuroblastoma incidence, survival, and racial and ethnic disparities from 2001 to 2019. Pediatr Blood Cancer. 2024 Jan;71(1):e30732.[Abstract][Full Text]

17. Kamihara J, Diller LR, Foulkes WD, et al. Neuroblastoma predisposition and surveillance - an update from the 2023 AACR Childhood Cancer Predisposition Workshop. Clin Cancer Res. 2024 Aug 1;30(15):3137-43.[Abstract][Full Text]

18. Mossé YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008 Oct 16;455(7215):930-5.[Abstract][Full Text]

19. Windels ML, Cordier F, Van Dorpe J, et al. PHOX2B: a diagnostic cornerstone in neurocristopathies and neuroblastomas. J Clin Pathol. 2024 May 17;77(6):378-82.[Abstract]

20. Raabe EH, Laudenslager M, Winter C, et al. Prevalence and functional consequence of PHOX2B mutations in neuroblastoma. Oncogene. 2008 Jan 17;27(4):469-76.[Abstract]

21. Barr EK, Applebaum MA. Genetic predisposition to neuroblastoma. Children (Basel). 2018 Aug 31;5(9):119.[Abstract][Full Text]

22. Kamihara J, Bourdeaut F, Foulkes WD, et al. Retinoblastoma and neuroblastoma predisposition and surveillance. Clin Cancer Res. 2017 Jul 1;23(13):e98-e106.[Abstract][Full Text]

23. Del Bufalo F, De Angelis B, Caruana I, et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N Engl J Med. 2023 Apr 6;388(14):1284-95.[Abstract][Full Text]

24. Sait S, Modak S. Anti-GD2 immunotherapy for neuroblastoma. Expert Rev Anticancer Ther. 2017 Oct;17(10):889-904.[Abstract]

25. Salim A, Raitio A, Pizer B, et al. Neuroblastoma: the association of anatomical tumour site, molecular biology and patient outcomes. ANZ J Surg. 2021 May;91(5):1000-4.[Abstract][Full Text]

26. DuBois SG, Kalika Y, Lukens JN, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol. 1999 May-Jun;21(3):181-9.[Abstract]

27. Louis CU, Shohet JM. Neuroblastoma: molecular pathogenesis and therapy. Annu Rev Med. 2015;66:49-63.[Abstract][Full Text]

28. Pugh TJ, Morozova O, Attiyeh EF, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013 Mar;45(3):279-84.[Abstract][Full Text]

29. Harding M, Deyell RJ, Blydt-Hansen T. Catecholamines in neuroblastoma: driver of hypertension, or solely a marker of disease? Cancer Rep (Hoboken). 2022 Aug;5(8):e1569.[Abstract][Full Text]

30. Barco S, Gennai I, Reggiardo G, et al. Urinary homovanillic and vanillylmandelic acid in the diagnosis of neuroblastoma: report from the Italian Cooperative Group for Neuroblastoma. Clin Biochem. 2014 Jun;47(9):848-52.[Abstract]

31. Honda T, Tanaka K, Honma T, et al. Development of neuroblastoma during growth hormone therapy for short stature in a girl with mosaic turner syndrome. Cureus. 2025 Jan;17(1):e77747.[Abstract][Full Text]

32. Pinsker JE, Crudo DF. Ganglioneuroblastoma in a young child with Turner syndrome. J Pediatr Endocrinol Metab. 2012;25(7-8):799-800.[Abstract]

33. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: neuroblastoma [internet publication].​[Full Text]

34. Bartolucci D, Montemurro L, Raieli S, et al. MYCN impact on high-risk neuroblastoma: from diagnosis and prognosis to targeted treatment. Cancers (Basel). 2022 Sep 12;14(18):4421.[Abstract][Full Text]

35. Ambros PF, Ambros IM, Brodeur GM, et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer. 2009 May 5;100(9):1471-82.[Abstract][Full Text]

36. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993 Aug;11(8):1466-77.[Abstract]

37. Kamihara J, Bourdeaut F, Foulkes WD, et al. Retinoblastoma and Neuroblastoma Predisposition and Surveillance. Clin Cancer Res. 2017 Jul 1;23(13):e98-e106.[Abstract][Full Text]

38. Granja C, Mota L. Paediatric neuroblastoma presenting as an asymptomatic abdominal mass: a report on the importance of a complete clinical examination with a view to a timely diagnosis and therapeutic guidance in paediatric oncology. BMJ Case Rep. 2022 May 19;15(5):e247907.[Abstract][Full Text]

39. Chu CM, Rasalkar DD, Hu YJ, et al. Clinical presentations and imaging findings of neuroblastoma beyond abdominal mass and a review of imaging algorithm. Br J Radiol. 2011 Jan;84(997):81-91.[Abstract][Full Text]

40. Fang X, Wang H, Ma X, et al. Clinical features of children with retinoblastoma and neuroblastoma. J Ophthalmol. 2020 Jul 10;2020:9315784.[Abstract][Full Text]

41. Raitio A, Rice MJ, Mullassery D, et al. Stage 4S Neuroblastoma: what are the outcomes? A systematic review of published studies. Eur J Pediatr Surg. 2021 Oct;31(5):385-9.[Abstract]

42. Rudnick E, Khakoo Y, Antunes NL, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study. Med Pediatr Oncol. 2001 Jun;36(6):612-22.[Abstract]

43. Rossor T, Yeh EA, Khakoo Y, et al. Diagnosis and management of opsoclonus-myoclonus-ataxia syndrome in children: an international perspective. Neurol Neuroimmunol Neuroinflamm. 2022 May;9(3):e1153.[Abstract][Full Text]

44. El-Enany G, Nagui NA, Hilal RF. Stage IV adrenal neuroblastoma with subcutaneous nodules in an infant: a case report. Int J Dermatol. 2020 Aug;59(8):e274-6.[Abstract]

45. Kazanowska B, Reich A, Jelen M, et al. Chronic metastatic neuroblastoma. Pediatr Blood Cancer. 2008 Apr;50(4):898-900.[Abstract]

46. Park JR, Bagatell R, Cohn SL, et al. Revisions to the International Neuroblastoma Response Criteria: a consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2017 Aug 1;35(22):2580-7.[Abstract][Full Text]

47. Campagna G, Rosenfeld E, Foster J, et al. Evolving biopsy techniques for the diagnosis of neuroblastoma in children. J Pediatr Surg. 2018 Nov;53(11):2235-9.[Abstract]

48. Agrawal A, Rangarajan V, Shah S, et al. MIBG (metaiodobenzylguanidine) theranostics in pediatric and adult malignancies. Br J Radiol. 2018 Nov;91(1091):20180103.[Abstract][Full Text]

49. Hawthorne HC Jr, Nelson JS, Witzleben CL, et al. Blanching subcutaneous nodules in neonatal neuroblastoma. J Pediatr. 1970 Aug;77(2):297-300.[Abstract]

50. Qiu B, Matthay KK. Advancing therapy for neuroblastoma. Nat Rev Clin Oncol. 2022 Aug;19(8):515-33.[Abstract][Full Text]

51. Defferrari R, Mazzocco K, Ambros IM, et al. Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification. Br J Cancer. 2015 Jan 20;112(2):290-5.[Abstract][Full Text]

52. Bosse KR, Maris JM. Advances in the translational genomics of neuroblastoma: from improving risk stratification and revealing novel biology to identifying actionable genomic alterations. Cancer. 2016 Jan 1;122(1):20-33.[Abstract][Full Text]

53. Kaplan SJ, Holbrook CT, McDaniel HG, et al. Vasoactive intestinal peptide secreting tumors of childhood. Am J Dis Child. 1980 Jan;134(1):21-4.[Abstract]

54. Bleeker G, Tytgat GA, Adam JA, et al. 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma. Cochrane Database Syst Rev. 2015 Sep 29;2015(9):CD009263.[Abstract][Full Text]

55. Samim A, Tytgat GAM, Bleeker G, et al. Nuclear medicine imaging in neuroblastoma: current status and new developments. J Pers Med. 2021 Apr 4;11(4):270.[Abstract][Full Text]

56. Spreafico F, Fernandez CV, Brok J, et al. Wilms tumour. Nat Rev Dis Primers. 2021 Oct 14;7(1):75.[Abstract]

57. Grünewald TGP, Cidre-Aranaz F, Surdez D, et al. Ewing sarcoma. Nat Rev Dis Primers. 2018 Jul 5;4(1):5.[Abstract]

58. Skapek SX, Ferrari A, Gupta AA, et al. Rhabdomyosarcoma. Nat Rev Dis Primers. 2019 Jan 7;5(1):1.[Abstract][Full Text]

59. Nussbaumer G, Benesch M. Hepatoblastoma in molecularly defined, congenital diseases. Am J Med Genet A. 2022 Sep;188(9):2527-35.[Abstract][Full Text]

60. Connors JM, Cozen W, Steidl C, et al. Hodgkin lymphoma. Nat Rev Dis Primers. 2020 Jul 23;6(1):61.[Abstract]

61. Khuri FJ, Alton DJ, Hardy BE, Cook GT, Churchill BM. Adrenal hemorrhage in neonates: report of 5 cases and review of the literature. J Urol. 1980 Nov;124(5):684-7.[Abstract]

62. Vukelic D, Bozinovic D, Morovic M, et al. Opsoclonus-myoclonus syndrome in a child with neuroborreliosis. J Infect. 2000 Mar;40(2):189-91.[Abstract]

63. Sheth RD, Horwitz SJ, Aronoff S, et al. Opsoclonus myoclonus syndrome secondary to Epstein-Barr virus infection. J Child Neurol. 1995 Jul;10(4):297-9.[Abstract]

64. Ertekin V, Tan H. Opsoclonus-myoclonus syndrome attributable to hepatitis C infection. Pediatr Neurol. 2010 Jun;42(6):441-2.[Abstract]

65. Cardesa-Salzmann TM, Mora J, García Cazorla MA, et al. Epstein-Barr virus related opsoclonus-myoclonus-ataxia does not rule out the presence of occult neuroblastic tumors. Pediatr Blood Cancer. 2006 Dec;47(7):964-7.[Abstract]

66. Candler PM, Dale RC, Griffin S, et al. Post-streptococcal opsoclonus-myoclonus syndrome associated with anti-neuroleukin antibodies. J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):507-12.[Abstract][Full Text]

67. Irwin MS, Naranjo A, Zhang FF, et al. Revised neuroblastoma risk classification system: a report from the Children's Oncology Group. J Clin Oncol. 2021 Oct 10;39(29):3229-41.[Abstract]

68. UK National Screening Committee. Neuroblastoma: ​child screening programme. 2016 [internet publication].[Full Text]

69. Sokol E, Desai AV, Applebaum MA, et al. Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project. J Clin Oncol. 2020 Jun 10;38(17):1906-18.[Abstract][Full Text]

70. Schleiermacher G, Mosseri V, London WB, et al. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. Br J Cancer. 2012 Oct 9;107(8):1418-22.[Abstract][Full Text]

71. Irwin MS, Goldsmith KC. Current and emerging biomarkers: impact on risk stratification for neuroblastoma. J Natl Compr Canc Netw. 2024 Aug;22(6):e247051.[Abstract][Full Text]

72. Otte J, Dyberg C, Pepich A, et al. MYCN function in neuroblastoma development. Front Oncol. 2021 Jan 27;10:624079.[Abstract][Full Text]

73. Schmidt ML, Lal A, Seeger RC, et al. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol. 2005 Sep 20;23(27):6474-80.[Abstract][Full Text]

74. London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol. 2005 Sep 20;23(27):6459-65.[Abstract][Full Text]

75. George RE, London WB, Cohn SL, et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 2005 Sep 20;23(27):6466-73.[Abstract][Full Text]

76. Yamamoto K, Hanada R, Kikuchi A, et al. Spontaneous regression of localized neuroblastoma detected by mass screening. J Clin Oncol. 1998 Apr;16(4):1265-9.[Abstract]

77. Oue T, Inoue M, Yoneda A, et al. Profile of neuroblastoma detected by mass screening, resected after observation without treatment: results of the Wait and See pilot study. J Pediatr Surg. 2005 Feb;40(2):359-63.[Abstract]

78. Okazaki T, Kohno S, Mimaya J, et al. Neuroblastoma detected by mass screening: the Tumor Board's role in its treatment. Pediatr Surg Int. 2004 Jan;20(1):27-32.[Abstract]

79. Nishihira H, Toyoda Y, Tanaka Y, et al. Natural course of neuroblastoma detected by mass screening: s 5-year prospective study at a single institution. J Clin Oncol. 2000 Aug;18(16):3012-7.[Abstract]

80. Strother DR, London WB, Schmidt ML, et al. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. J Clin Oncol. 2012 May 20;30(15):1842-8.[Abstract][Full Text]

81. Baker DL, Schmidt ML, Cohn SL, et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010 Sep 30;363(14):1313-23.[Abstract][Full Text]

82. Strother D, van Hoff J, Rao PV, et al. Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Pediatric Oncology Group. Eur J Cancer. 1997 Oct;33(12):2121-5.[Abstract]

83. Strother D, Shuster JJ, McWilliams N, et al. Results of pediatric oncology group protocol 8104 for infants with stages D and DS neuroblastoma. J Pediatr Hematol Oncol. 1995 Aug;17(3):254-9.[Abstract]

84. Mullassery D, Farrelly P, Losty PD. Does aggressive surgical resection improve survival in advanced stage 3 and 4 neuroblastoma? A systematic review and meta-analysis. Pediatr Hematol Oncol. 2014 Nov;31(8):703-16.[Abstract]

85. Krystal J, Foster JH. Treatment of high-risk neuroblastoma. Children (Basel). 2023 Jul 28;10(8):1302.[Abstract][Full Text]

86. Yang X, Chen J, Wang N, et al. Impact of extent of resection on survival in high-risk neuroblastoma: A systematic review and meta-analysis. J Pediatr Surg. 2019 Jul;54(7):1487-94.[Abstract]

87. Seemann NM, Erker C, Irwin MS, et al. Survival effect of complete surgical resection of the primary tumor in patients with metastatic, high-risk neuroblastoma in a large Canadian cohort. Pediatr Blood Cancer. 2023 Jun;70(6):e30286.[Abstract]

88. Fischer J, Pohl A, Volland R, et al. Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months. BMC Cancer. 2017 Aug 4;17(1):520.[Abstract][Full Text]

89. Holmes K, Pötschger U, Pearson ADJ, et al. Influence of surgical excision on the survival of patients with stage 4 high-risk neuroblastoma: a report from the HR-NBL1/SIOPEN study. J Clin Oncol. 2020 Sep 1;38(25):2902-15.[Abstract][Full Text]

90. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999 Oct 14;341(16):1165-73.[Abstract][Full Text]

91. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009 Mar 1;27(7):1007-13.[Abstract][Full Text]

92. Laprie A, Michon J, Hartmann O, et al. High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system stage II and III neuroblastoma with MYCN amplification. Cancer. 2004 Sep 1;101(5):1081-9.[Abstract][Full Text]

93. Desai AV, Heneghan MB, Li Y, et al. Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma. Bone Marrow Transplant. 2016 Sep;51(9):1204-10.[Abstract]

94. Proust-Houdemont S, Pasqualini C, Blanchard P, et al. Busulfan-melphalan in high-risk neuroblastoma: the 30-year experience of a single institution. Bone Marrow Transplant. 2016 Aug;51(8):1076-81.[Abstract]

95. Park JR, Kreissman SG, London WB, et al. Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial. JAMA. 2019 Aug 27;322(8):746-55.[Abstract][Full Text]

96. Peinemann F, van Dalen EC, Enk H, et al. Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2019 Apr 24;4:CD012442.[Abstract][Full Text]

97. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010 Sep 30;363(14):1324-34.[Abstract][Full Text]

98. Bassiri H, Benavides A, Haber M, et al. Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma. Transl Pediatr. 2015 Jul;4(3):226-38.[Abstract][Full Text]

99. Saulnier Sholler GL, Gerner EW, Bergendahl G, et al. A phase I trial of DFMO targeting polyamine addiction in patients with relapsed/refractory neuroblastoma. PLoS One. 2015 May 27;10(5):e0127246.[Abstract][Full Text]

100. Sholler GLS, Ferguson W, Bergendahl G, et al. Maintenance DFMO Increases Survival in High Risk Neuroblastoma. Sci Rep. 2018 Sep 27;8(1):14445.[Abstract][Full Text]

101. Oesterheld J, Ferguson W, Kraveka JM, et al. Eflornithine as postimmunotherapy maintenance in high-risk neuroblastoma: externally controlled, propensity score-matched survival outcome comparisons. J Clin Oncol. 2024 Jan 1;42(1):90-102.[Abstract][Full Text]

102. Mody R, Naranjo A, Van Ryn C, et al. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol. 2017;18(7):946-57.[Abstract][Full Text]

103. Markham A. Naxitamab: First Approval. Drugs. 2021 Feb;81(2):291-96.[Abstract]

104. ​Mora J, Chan G, Morgenstern DA, et al. 891P Naxitamab treatment for relapsed or refractory high-risk neuroblastoma: outcomes from the first prespecified analyses of the Pivotal 201 Trial. Ann Oncol. 2022;33(S7):S956.[Full Text]

105. ​Kushner BH, Modak S, Basu E, et al. High-dose naxitamab (humanized-3F8) plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor (GM-CSF) for resistant osteomedullary neuroblastoma: major responses and outpatient treatment in a phase II trial [abstract]. Pediatr Blood Cancer. 2020;67(Suppl 4):S32.[Full Text]

106. Zhou MJ, Doral MY, DuBois SG, et al. Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG). Eur J Cancer. 2015 Nov;51(16):2465-72.[Abstract]

107. Wilson JS, Gains JE, Moroz V, et al. A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma. Eur J Cancer. 2014 Mar;50(4):801-15.[Abstract]

108. George SL, Falzone N, Chittenden S, et al. Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma. Nucl Med Commun. 2016 May;37(5):466-72.[Abstract]

109. Nuchtern JG, London WB, Barnewolt CE, et al. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study. Ann Surg. 2012 Oct;256(4):573-80.[Abstract]

110. Nickerson HJ, Matthay KK, Seeger RC, et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol. 2000 Feb;18(3):477-86.[Abstract]

111. Katzenstein HM, Bowman LC, Brodeur GM, et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience - a pediatric oncology group study. J Clin Oncol. 1998 Jun;16(6):2007-17.[Abstract]

112. Woods WG, Gao RN, Shuster JJ, et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med. 2002 Apr 4;346(14):1041-6.[Abstract][Full Text]

113. Schilling FH, Spix C, Berthold F, et al. Neuroblastoma screening at one year of age. N Engl J Med. 2002 Apr 4;346(14):1047-53.[Abstract][Full Text]

114. Acharya S, Jayabose S, Kogan SJ, et al. Prenatally diagnosed neuroblastoma. Cancer. 1997 Jul 15;80(2):304-10.[Abstract]

115. Weiss BD, Yanik G, Naranjo A, et al. A safety and feasibility trial of (131) I-MIBG in newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. Pediatr Blood Cancer. 2021 Oct;68(10):e29117.[Abstract]

116. Mastrangelo S, Attinà G, Zagaria L, et al. Induction regimen in high-risk neuroblastoma: a pilot study of highly effective continuous exposure of tumor cells to radio-chemotherapy sequence for 1 month. The critical role of iodine-131-metaiodobenzylguanidine. Cancers (Basel). 2022 Oct 21;14(20):5170.[Abstract][Full Text]

117. ClinicalTrials.gov. Testing the addition of 131I-MIBG or lorlatinib to intensive therapy in people with high-risk neuroblastoma (NBL). ClinicalTrials.gov Identifier: NCT03126916.​ Mar 2025 [internet publication].[Full Text]

118. Goldsmith KC, Park JR, Kayser K, et al. Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results. Nat Med. 2023 May;29(5):1092-102.[Abstract][Full Text]

119. Cole KA, Ijaz H, Surrey LF, et al. Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma. Cancer. 2023 Jul 15;129(14):2245-55.[Abstract][Full Text]

120. Corbacioglu S, Lode H, Ellinger S, et al. Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2024 Jul;25(7):922-32.[Abstract][Full Text]

121. Li CH, Sharma S, Heczey AA, et al. Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma. Nat Med. 2025 Apr;31(4):1125-9.[Abstract]

122. Heczey A, Xu X, Courtney AN, et al. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2023 Jun;29(6):1379-88.[Abstract]

123. Yu L, Huang L, Lin D, et al. GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients. J Cancer Res Clin Oncol. 2022 Oct;148(10):2643-52.[Abstract][Full Text]

124. ClinicalTrials.gov. Neuroblastoma, car-T cell therapy, phase: 2 [internet publication]​.[Full Text]

125. Umaretiya PJ, Naranjo A, Zhang FF, et al. Racial and ethnic survival disparities among children with high-risk neuroblastoma: a Children's Oncology Group report. JAMA Netw Open. 2025 Feb 3;8(2):e2458531.[Abstract][Full Text]

126. Nofi CP, Roberts BK, Brown EG, et al. Social determinants of health influence on survival in wilms tumor, neuroblastoma, and hepatoblastoma. J Pediatr Surg. 2025 Apr;60(4):162216.[Abstract][Full Text]

127. Farouk FS, Viqar OA, Sheikh Z, et al. The association between race and survival among Pediatric Patients with Neuroblastoma in the US between 1973 and 2015. Int J Environ Res Public Health. 2020 Jul 15;17(14):5119.[Abstract][Full Text]

128. Chennakesavalu M, Pudela C, Applebaum MA, et al. Persistence of racial and ethnic disparities in risk and survival for patients with neuroblastoma over two decades. EJC Paediatr Oncol. 2023 Dec;2:100022.[Abstract][Full Text]

129. Moreno L, Rubie H, Varo A, et al. Outcome of children with relapsed or refractory neuroblastoma: a meta-analysis of ITCC/SIOPEN European phase II clinical trials. Pediatr Blood Cancer. 2017 Jan;64(1):25-31.[Abstract][Full Text]

130. London WB, Bagatell R, Weigel BJ, et al. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials. Cancer. 2017 Dec 15;123(24):4914-23.[Abstract][Full Text]

131. Friedman DN, Goodman PJ, Leisenring WM, et al. Impact of risk-based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2024 Jun 7;116(6):885-94.[Abstract][Full Text]

132. Haghiri S, Fayech C, Mansouri I, et al. Long-term follow-up of high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell transplantation rescue. Bone Marrow Transplant. 2021 Aug;56(8):1984-97.[Abstract]

133. Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of anthracyclines. Front Cardiovasc Med. 2020;7:26.[Abstract][Full Text]

134. Moreno L, Vaidya SJ, Pinkerton CR, et al. Long-term follow-up of children with high-risk neuroblastoma: the ENSG5 trial experience. Pediatr Blood Cancer. 2013 Jul;60(7):1135-40.[Abstract]

135. Landier W, Knight K, Wong FL, et al. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales - a report from the Children's Oncology Group. J Clin Oncol. 2014 Feb 20;32(6):527-34.[Abstract][Full Text]

136. Hobbie WL, Moshang T, Carlson CA, et al. Late effects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma. Pediatr Blood Cancer. 2008 Nov;51(5):679-83.[Abstract][Full Text]

137. Grewal S, Merchant T, Reymond R, et al. Auditory late effects of childhood cancer therapy: a report from the Children's Oncology Group. Pediatrics. 2010 Apr;125(4):e938-50.[Abstract][Full Text]

138. French AE, Irwin MS, Navarro OM, et al. Long-term hepatic outcomes in survivors of stage 4S and 4 neuroblastoma in infancy. Pediatr Blood Cancer. 2012 Feb;58(2):283-8.[Abstract]

139. van Casteren NJ, van der Linden GH, Hakvoort-Cammel FG, et al. Effect of childhood cancer treatment on fertility markers in adult male long-term survivors. Pediatr Blood Cancer. 2009 Jan;52(1):108-12.[Abstract]

140. Ducassou A, Gambart M, Munzer C, et al. Long-term side effects of radiotherapy for pediatric localized neuroblastoma : results from clinical trials NB90 and NB94. Strahlenther Onkol. 2015 Jul;191(7):604-12.[Abstract]

141. Kelly J, Damron T, Grant W, et al. Cross-sectional study of bone mineral density in adult survivors of solid pediatric cancers. J Pediatr Hematol Oncol. 2005 May;27(5):248-53.[Abstract]

142. Simon T, Niemann CA, Hero B, et al. Short- and long-term outcome of patients with symptoms of spinal cord compression by neuroblastoma. Dev Med Child Neurol. 2012 Apr;54(4):347-52.[Abstract][Full Text]

143. Cohen LE, Gordon JH, Popovsky EY, et al. Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: high incidence of endocrine and growth problems. Bone Marrow Transplant. 2014 Apr;49(4):502-8.[Abstract][Full Text]

144. Applebaum MA, Henderson TO, Lee SM, et al. Second malignancies in patients with neuroblastoma: the effects of risk-based therapy. Pediatr Blood Cancer. 2015 Jan;62(1):128-33.[Abstract][Full Text]

145. Applebaum MA, Vaksman Z, Lee SM, et al. Neuroblastoma survivors are at increased risk for second malignancies: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2017 Feb;72:177-85.[Abstract]